Hedgehog pathway inhibitor HhAntag691 is a potent inhibitor of ABCG2/BCRP and ABCB1/Pgp

Neoplasia

Volumn 11, Issue 1, 2009, Pages 96-101

  Zhang, Yimao ^a   Laterra, John ^a   Pomper, Martin G ^a  

^a DEPARTMENT OF PATHOLOGY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

7 ETHYL 10 HYDROXYCAMPTOTHECIN; ABC TRANSPORTER; ANTINEOPLASTIC AGENT; BREAST CANCER RESISTANCE PROTEIN; CALCEIN; COLCHICINE; GDC 0449; MITOXANTRONE; MULTIDRUG RESISTANCE PROTEIN 1; PRAZOSIN; SONIC HEDGEHOG PROTEIN; TOPOTECAN; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; BLOOD BRAIN BARRIER; CANCER THERAPY; CARCINOMA CELL; CELL STRAIN HEK293; CONTROLLED STUDY; FLUORESCENCE; HUMAN; HUMAN CELL; IC 50; LUNG NON SMALL CELL CANCER; MULTIDRUG RESISTANCE; NERVE FIBER; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; SENSITIZATION; SIGNAL TRANSDUCTION; TREATMENT FAILURE;

EID: 58249116119     PISSN: 15228002     EISSN: 14765586     Source Type: Journal    
DOI: 10.1593/neo.81264     Document Type: Article

References (47)

1. Romer JT, Kimura H, Magdaleno S, Sasai K, Fuller C, Baines H, Connelly M, Stewart CF, Gould S, Rubin LL, et al. (2004). Suppression of the Shh pathway using a small molecule inhibitor eliminates medulloblastoma in Ptc1(+/-)p53(-/-) mice. Cancer Cell 6, 229-240.
2. Chari NS and McDonnell TJ (2007). The sonic hedgehog signaling network in development and neoplasia. Adv Anat Pathol 14, 344-352.
3. Sasai K, Romer JT, Kimura H, Eberhart DE, Rice DS, and Curran T (2007). Medulloblastomas derived from Cxcr6 mutant mice respond to treatment with a smoothened inhibitor. Cancer Res 67, 3871-3877.
4. Tabs S and Avci O (2004). Induction of the differentiation and apoptosis of tumor cells in vivo with efficiency and selectivity. Eur J Dermatol 14, 96-102.
5. Mimeault M, Moore E, Moniaux N, Henichart JP, Depreux P, Lin MF, and Batra SK (2006). Cytotoxic effects induced by a combination of cyclopamine and gefitinib, the selective hedgehog and epidermal growth factor receptor signaling inhibitors, in prostate cancer cells. Int J Cancer 118, 1022-1031.
6. Bar EE, Chaudhry A, Lin A, Fan X, Schreck K, Matsui W, Piccirillo S, Vescovi AL, DiMeco F, Olivi A, et al. (2007). Cyclopamine-mediated hedgehog pathway inhibition depletes stem-like cancer cells in glioblastoma. Stem Cells 25, 2524-2533.
7. Berman DM, Karhadkar SS, Hallahan AR, Pritchard JI, Eberhart CG, Watkins DN, Chen JK, Cooper MK, Taipale J, Olson JM, et al. (2002). Medulloblastoma growth inhibition by hedgehog pathway blockade. Science 297, 1559-1561.
8. Szakacs G, Paterson JK, Ludwig JA, Booth-Genthe C, and Gottesman MM (2006). Targeting multidrug resistance in cancer. Nat Rev Drug Discov 5, 219-234.
9. Ailles LE and Weissman IL (2007). Cancer stem cells in solid tumors. Curr Opin Biotechnol 18, 460-466.
10. Zhou S, Schuetz JD, Bunting KD, Colapietro AM, Sampath J, Morris JJ, Lagutina I, Grosveld GC, Osawa M, Nakauchi H, et al. (2001). The ABC transporter Bcrp1/ABCG2 is expressed in a wide variety of stem cells and is a molecular determinant of the side-population phenotype. Nat Med 7, 1028-1034.
11. Stingl J and Caldas C (2007). Molecular heterogeneity of breast carcinomas and the cancer stem cell hypothesis. Nat Rev Cancer 7, 791-799.
12. Natarajan TG and FitzGerald KT (2007). Markers in normal and cancer stem cells. Cancer Biomark 3, 211-231.
13. Lou H and Dean M (2007). Targeted therapy for cancer stem cells: the patched pathway and ABC transporters. Oncogene 26, 1357-1360.
14. Sims-Mourtada J, Izzo JG, Ajani J, and Chao KS (2007). Sonic Hedgehog promotes multiple drug resistance by regulation of drug transport. Oncogene 26, 5674-5679.
15. Zhang Y, Bressler JP, Neal J, Lal B, Bhang H-E, Laterra J, and Pomper MG (2007). ABCG2/BCRP expression modulates D-luciferin based bioluminescence imaging. Cancer Res 67, 9389-9397.
16. Ray P, De A, Min JJ, Tsien RY, and Gambhir SS (2004). Imaging tri-fusion multimodality reporter gene expression in living subjects. Cancer Res 64, 1323-1330.
17. Evers R, Kool M, Smith AJ, van Deemter L, de Haas M, and Borst P (2000). Inhibitory effect of the reversal agents V-104, GF120918 and Pluronic L61 on MDR1 Pgp-, MRP1- and MRP2-mediated transport. Br J Cancer 83, 366-374.
18. Robey RW, Honjo Y, Morisaki K, Nadjem TA, Runge S, Risbood M, Poruchynsky MS, and Bates SE (2003). Mutations at amino acid 482 in the ABCG2 gene affect substrate and antagonist specificity. Br J Cancer 89, 1971-1978.
19. Robey RW, Honjo Y, van de Laar A, Miyake K, Regis JT, Litman T, and Bates SE (2001). A functional assay for detection of the mitoxantrone resistance protein, MXR (ABCG2). Biochim Biophys Acta 1512, 171-182.
20. Homolya L, Hollo Z, Germann UA, Pastan I, Gottesman MM, and Sarkadi B (1993). Fluorescent cellular indicators are extruded by the multidrug resistance protein. J Biol Chem 268, 21493-21496.
21. Hollo Z, Homolya L, Hegedus T, and Sarkadi B (1996). Transport properties of the multidrug resistance-associated protein (MRP) in human tumour cells. FEBS Lett 383, 99-104.
22. Alley MC, Scudiero DA, Monks A, Hursey ML, Czerwinski MJ, Fine DL, Abbott BJ, Mayo JG, Shoemaker RH, and Boyd MR (1988). Feasibility of drug screening with panels of human tumor cell lines using a microculture tetrazolium assay. Cancer Res 48, 589-601.
23. Scudiero DA, Shoemaker RH, Paull KD, Monks A, Tierney S, Nofziger TH, Currens MJ, Seniff D, and Boyd MR (1988). Evaluation of a soluble tetrazolium/formazan assay for cell growth and drug sensitivity in culture using human and other tumor cell lines. Cancer Res 48, 4827-4833.
24. Rabindran SK, Ross DD, Doyle LA, Yang W, and Greenberger LM (2000). Fumitremorgin C reverses multidrug resistance in cells transfected with the breast cancer resistance protein. Cancer Res 60, 47-50.
25. Gross S and Piwnica-Worms D (2005). Spying on cancer: molecular imaging in vivo with genetically encoded reporters. Cancer Cell 7, 5-15.
26. Doyle LA, Yang W, Abruzzo LV, Krogmann T, Gao Y, Rishi AK, and Ross DD (1998). A multidrug resistance transporter from human MCF-7 breast cancer cells. Proc Natl Acad Sci USA 95, 15665-15670.
27. Ambudkar SV, Dey S, Hrycyna CA, Ramachandra M, Pastan I, and Gottesman MM (1999). Biochemical, cellular, and pharmacological aspects of the multidrug transporter. Annu Rev Pharmacol Toxicol 39, 361-398.
28. Shen DW, Cardarelli C, Hwang J, Cornwell M, Richert N, Ishii S, Pastan I, and Gottesman MM (1986). Multiple drug-resistant human KB carcinoma cells independently selected for high-level resistance to colchicine, adriamycin, or vinblastine show changes in expression of specific proteins. J Biol Chem 261, 7762-7770.
29. Klappe K, Hinrichs JW, Kroesen BJ, Sietsma H, and Kok JW (2004). MRP1 and glucosylceramide are coordinately over expressed and enriched in rafts during multidrug resistance acquisition in colon cancer cells. Int J Cancer 110, 511-522.
30. Litman T, Brangi M, Hudson E, Fetsch P, Abati A, Ross DD, Miyake K, Resau JH, and Bates SE (2000). The multidrug-resistant phenotype associated with overexpression of the new ABC half-transporter, MXR (ABCG2). J Cell Sci 113 (Pt 11), 2011-2021.
31. Kawabata S, Oka M, Shiozawa K, Tsukamoto K, Nakatomi K, Soda H, Fukuda M, Ikegami Y, Sugahara K, Yamada Y, et al. (2001). Breast cancer resistance protein directly confers SN-38 resistance of lung cancer cells. Biochem Biophys Res Commun 280, 1216-1223.
32. Brangi M, Litman T, Ciotti M, Nishiyama K, Kohlhagen G, Takimoto C, Robey R, Pommier Y, Fojo T, and Bates SE (1999). Camptothecin resistance: role of the ATP-binding cassette (ABC), mitoxantrone-resistance half-transporter (MXR), and potential for glucuronidation in MXR-expressing cells. Cancer Res 59, 5938-5946.
33. Begley DJ (2004). ABC transporters and the blood-brain barrier. Curr Pharm Des 10, 1295-1312.
34. Baselga J and Averbuch SD (2000). ZD1839 ("Iressa") as an anticancer agent. Drugs 60 (Suppl 1), 33-40, discussion 41-42.
35. Nakamura Y, Oka M, Soda H, Shiozawa K, Yoshikawa M, Itoh A, Ikegami Y, Tsurutani J, Nakatomi K, Kitazaki T, et al. (2005). Gefitinib ("Iressa", ZD1839), an epidermal growth factor receptor tyrosine kinase inhibitor, reverses breast cancer resistance protein/ABCG2-mediated drug resistance. Cancer Res 65, 1541-1546.
36. Elkind NB, Szentpetery Z, Apati A, Ozvegy-Laczka C, Varady G, Ujhelly O, Szabo K, Homolya L, Varadi A, Buday L, et al. (2005). Multidrug transporter ABCG2 prevents tumor cell death induced by the epidermal growth factor receptor inhibitor Iressa (ZD1839, gefitinib). Cancer Res 65, 1770-1777.
37. Houghton PJ, Germain GS, Harwood FC, Schuetz JD, Stewart CF, Buchdunger E, and Traxler P (2004). Imatinib mesylate is a potent inhibitor of the ABCG2 (BCRP) transporter and reverses resistance to topotecan and SN-38 in vitro. Cancer Res 64, 2333-2337.
38. Shi Z, Peng XX, Kim IW, Shukla S, Si QS, Robey RW, Bates SE, Shen T, Ashby CR Jr, Fu LW, et al. (2007). Erlotinib (Tarceva, OSI-774) antagonizes ATP-binding cassette subfamily B member 1 and ATP-binding cassette subfamily G member 2-mediated drug resistance. Cancer Res 67, 11012-11020.
39. Ozvegy-Laczka C, Hegedus T, Varady G, Ujhelly O, Schuetz JD, Varadi A, Keri G, Orfi L, Nemet K, and Sarkadi B (2004). High-affinity interaction of tyrosine kinase inhibitors with the ABCG2 multidrug transporter. Mol Pharmacol 65, 1485-1495.
40. Dai H, Marbach P, Lemaire M, Hayes M, and Elmquist WF (2003). Distribution of STI-571 to the brain is limited by P-glycoprotein-mediated efflux. J Pharmacol Exp Ther 304, 1085-1092.
41. Weiss J, Rose J, Storch CH, Ketabi-Kiyanvash N, Sauer A, Haefeli WE, and Efferth T (2007). Modulation of human BCRP (ABCG2) activity by anti-HIV drugs. J Antimicrob Chemother 59, 238-245.
42. Chen JS, Pardo FS, Wang-Rodriguez J, Chu TS, Lopez JP, Aguilera J, Altuna X, Weisman RA, and Ongkeko WM (2006). EGFR regulates the side population in head and neck squamous cell carcinoma. Laryngoscope 116, 401-406.
43. Takada T, Suzuki H, Gotoh Y, and Sugiyama Y (2005). Regulation of the cell surface expression of human BCRP/ABCG2 by the phosphorylation state of Akt in polarized cells. Drug Metab Dispos 33, 905-909.
44. Meyer zu Schwabedissen HE, Grube M, Dreisbach A, Jedlitschky G, Meissner K, Linnemann K, Fusch C, Ritter CA, Volker U, and Kroemer HK (2006). Epidermal growth factor-mediated activation of the map kinase cascade results in altered expression and function of ABCG2 (BCRP). Drug Metab Dispos 34, 524-533.
45. Nakanishi T, Shiozawa K, Hassel BA, and Ross DD (2006). Complex interaction of BCRP/ABCG2 and imatinib in BCR-ABL-expressing cells: BCRP-mediated resistance to imatinib is attenuated by imatinib-induced reduction of BCRP expression. Blood 108, 678-684.
46. Xie Y, Xu K, Linn DE, Yang X, Guo Z, Shimelis H, Nakanishi T, Ross DD, Chen H, Fazli L, et al. (2008). The 44-kDa Pim-1 kinase phosphorylates BCRP/ABCG2 and thereby promotes its multimerization and drug-resistant activity in human prostate cancer cells. J Biol Chem 283, 3349-3356.
47. Dean M, Fojo T, and Bates S (2005). Tumour stem cells and drug resistance. Nat Rev Cancer 5, 275-284.